RTTNews | Dec 18, 2020 07:54AM EST

07:54 Friday, December 18, 2020 (RTTNews.com) - MacroGenics Inc. (MGNX) said that it has reached a research collaboration and global license agreement to develop a preclinical bispecific molecule with Janssen Biotech Inc. The research collaboration will incorporate MacroGenics' proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology.

As per the terms of the deal, Janssen will pay MacroGenics an upfront payment of $20 million and will be responsible for funding all expenses. MacroGenics will also be eligible to receive up to $312 million in potential milestone payments and tiered royalties on worldwide product sales. Further details about the transaction are not disclosed.

Read the original article on RTTNews ( https://www.rttnews.com/3154995/macrogenics-reaches-research-collaboration-with-janssen-to-get-up-to-332-mln-payments.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved